CN1230168C - 具有抗抑郁效果的药物 - Google Patents

具有抗抑郁效果的药物 Download PDF

Info

Publication number
CN1230168C
CN1230168C CNB998083038A CN99808303A CN1230168C CN 1230168 C CN1230168 C CN 1230168C CN B998083038 A CNB998083038 A CN B998083038A CN 99808303 A CN99808303 A CN 99808303A CN 1230168 C CN1230168 C CN 1230168C
Authority
CN
China
Prior art keywords
tetrahydro
amino
propylamino
benzothiazole
sertraline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998083038A
Other languages
English (en)
Chinese (zh)
Other versions
CN1308533A (zh
Inventor
杰兹·马吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1308533A publication Critical patent/CN1308533A/zh
Application granted granted Critical
Publication of CN1230168C publication Critical patent/CN1230168C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998083038A 1998-07-07 1999-07-02 具有抗抑郁效果的药物 Expired - Fee Related CN1230168C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19830201.0 1998-07-07
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (2)

Publication Number Publication Date
CN1308533A CN1308533A (zh) 2001-08-15
CN1230168C true CN1230168C (zh) 2005-12-07

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998083038A Expired - Fee Related CN1230168C (zh) 1998-07-07 1999-07-02 具有抗抑郁效果的药物

Country Status (32)

Country Link
US (1) US6255329B1 (https=)
EP (1) EP1093369B1 (https=)
JP (1) JP2002520273A (https=)
KR (1) KR100557692B1 (https=)
CN (1) CN1230168C (https=)
AR (1) AR019896A1 (https=)
AT (1) ATE228365T1 (https=)
AU (1) AU762128B2 (https=)
BG (1) BG64972B1 (https=)
BR (1) BR9911768A (https=)
CA (1) CA2336833C (https=)
CZ (1) CZ294087B6 (https=)
DE (2) DE19830201A1 (https=)
DK (1) DK1093369T3 (https=)
EA (1) EA003142B1 (https=)
EE (1) EE04296B1 (https=)
ES (1) ES2183583T3 (https=)
HU (1) HUP0103922A3 (https=)
ID (1) ID27776A (https=)
IL (1) IL140603A0 (https=)
MY (1) MY117969A (https=)
NO (1) NO20010064L (https=)
NZ (1) NZ509729A (https=)
PL (1) PL195043B1 (https=)
PT (1) PT1093369E (https=)
RS (1) RS49795B (https=)
SK (1) SK284923B6 (https=)
TR (1) TR200100146T2 (https=)
TW (1) TW592698B (https=)
WO (1) WO2000002542A2 (https=)
YU (1) YU401A (https=)
ZA (1) ZA200100090B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
WO2005070428A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
JP2012525426A (ja) * 2009-04-30 2012-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド うつ病を治療する方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
NZ325914A (en) * 1996-03-29 1999-09-29 Pfizer Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
EA200100084A1 (ru) 2001-08-27
KR20010079491A (ko) 2001-08-22
IL140603A0 (en) 2002-02-10
BG64972B1 (bg) 2006-11-30
RS49795B (sr) 2008-06-05
BR9911768A (pt) 2001-04-03
EP1093369B1 (de) 2002-11-27
ID27776A (id) 2001-04-26
CA2336833A1 (en) 2000-01-20
PL345842A1 (en) 2002-01-14
CZ294087B6 (cs) 2004-10-13
HUP0103922A2 (hu) 2002-03-28
EA003142B1 (ru) 2003-02-27
EE200100014A (et) 2002-06-17
WO2000002542A3 (de) 2000-06-22
KR100557692B1 (ko) 2006-03-07
HUP0103922A3 (en) 2002-08-28
EE04296B1 (et) 2004-06-15
TR200100146T2 (tr) 2001-07-23
CZ200177A3 (en) 2001-06-13
SK284923B6 (sk) 2006-02-02
ZA200100090B (en) 2002-04-04
ATE228365T1 (de) 2002-12-15
WO2000002542A2 (de) 2000-01-20
AU5030399A (en) 2000-02-01
NZ509729A (en) 2003-06-30
NO20010064D0 (no) 2001-01-05
SK112001A3 (en) 2001-10-08
DE59903556D1 (de) 2003-01-09
DK1093369T3 (da) 2002-12-16
AU762128B2 (en) 2003-06-19
CN1308533A (zh) 2001-08-15
AR019896A1 (es) 2002-03-20
CA2336833C (en) 2008-09-23
BG105112A (bg) 2001-10-31
JP2002520273A (ja) 2002-07-09
PL195043B1 (pl) 2007-08-31
YU401A (sh) 2003-10-31
ES2183583T3 (es) 2003-03-16
PT1093369E (pt) 2003-03-31
TW592698B (en) 2004-06-21
US6255329B1 (en) 2001-07-03
EP1093369A2 (de) 2001-04-25
MY117969A (en) 2004-08-30
HK1037976A1 (en) 2002-03-01
NO20010064L (no) 2001-03-02
DE19830201A1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
CN1230168C (zh) 具有抗抑郁效果的药物
CA2301899C (en) Agent with an antidepressant activity
CN1132581C (zh) 含米尔塔扎平和一种或多种选择性5－羟色胺再摄取抑制剂的药物组合物
CN1151785C (zh) 含有二甲双胍和贝特联合的药物组合物及其在制备降低高血糖药物中的应用
EP0415613A2 (en) Use of sertraline for the treatment of premature ejaculation
CN1512885A (zh) 药物组合
CN1726041A (zh) 含有非核苷反转录酶抑制剂(nnrti)以及细胞色素p450抑制剂如蛋白酶抑制剂的组合物的用途
AU2003240113A1 (en) Formulation of nefopam and its use in the treatment of pain
RU2192252C2 (ru) Применение прамипексола в лечении синдрома усталых ног
HK1037976B (en) Agents with an antidepressive effect
CN1298389C (zh) 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用
CN1859901A (zh) 含有加速作用开始的乙酰水杨酸的口服抗抑郁制剂
US20100152152A1 (en) Therapeutic Use of Nefopam
CN1259912C (zh) 用于治疗升高的血压的西酞普兰
CN1845730A (zh) 5－羟色胺再摄取抑制剂与克塞平的组合
CN1703216A (zh) 用于治疗多发性骨髓瘤的埃坡霉素衍生物
JP2006522786A (ja) 痙縮及びまたは疼痛治療用薬剤組合わせ
HK1085921A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
AU2001286798B2 (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
HK1096860A (en) Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action
CN1345237A (zh) 预防或降低与冠脉介入有关的心血管事件的方法
JP2013537232A5 (https=)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051207